Alternatives to DiaMedica Therapeutics

A clinical-stage biotechnology company developing in vivo gene editing therapies.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing novel therapeutics to restore gut lymphatic function.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Biopharmaceutical company developing and commercializing CNS disease treatments.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Enzyme-based technology to break down alcohol in the stomach.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Accelerating patient access to evidence-based innovation in mental health.

A biotechnology company developing genetic therapies for rare disorders.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Developing highly targeted, small molecule medicines.

Developing oral small molecule medicines for immunological and chronic diseases.

A pharmaceutical company focused on developing long-acting injectable medicines.

AI-powered antibody discovery platform.

Advancing next-generation mRNA medicines.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Clinical-stage biotech company targeting RNA modifications for novel cancer therapies.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Immunotherapy company targeting oncology and autoimmune diseases.

A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.

AI platform for engineering molecular glues to create a new class of medicines.

A biotechnology company focused on oncology drug discovery.

Developing first-in-class oral therapy for BK polyomavirus infections.

Clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders.

Developing small-molecule modulators of lysosomal ion channels for neurodegenerative diseases.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Developing novel male contraceptives.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Scalable, one-time curative in-vivo gene editing therapies.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Advancing targeted alpha therapies.

A biopharmaceutical company focused on drug discovery and development.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.